- Home
- XHG vs QLGN Comparison
XHG vs QLGN Comparison
Compare XHG & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XHG
- QLGN
- Stock Information
- Founded
- XHG 2012
- QLGN 1996
- Country
- XHG China
- QLGN United States
- Employees
- XHG N/A
- QLGN N/A
- Industry
- XHG
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- XHG
- QLGN Health Care
- Exchange
- XHG NYSE
- QLGN Nasdaq
- Market Cap
- XHG 2.5M
- QLGN 2.2M
- IPO Year
- XHG 2019
- QLGN N/A
- Fundamental
- Price
- XHG $1.56
- QLGN $3.87
- Analyst Decision
- XHG
- QLGN
- Analyst Count
- XHG 0
- QLGN 0
- Target Price
- XHG N/A
- QLGN N/A
- AVG Volume (30 Days)
- XHG 1.1M
- QLGN 44.7K
- Earning Date
- XHG 05-23-2025
- QLGN 07-01-2025
- Dividend Yield
- XHG N/A
- QLGN N/A
- EPS Growth
- XHG N/A
- QLGN N/A
- EPS
- XHG N/A
- QLGN N/A
- Revenue
- XHG $41,110,414.00
- QLGN N/A
- Revenue This Year
- XHG N/A
- QLGN N/A
- Revenue Next Year
- XHG N/A
- QLGN N/A
- P/E Ratio
- XHG N/A
- QLGN N/A
- Revenue Growth
- XHG N/A
- QLGN N/A
- 52 Week Low
- XHG $0.09
- QLGN $2.85
- 52 Week High
- XHG $60.00
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- XHG 30.31
- QLGN 61.76
- Support Level
- XHG $1.44
- QLGN $3.40
- Resistance Level
- XHG $3.23
- QLGN $3.95
- Average True Range (ATR)
- XHG 0.39
- QLGN 0.26
- MACD
- XHG 0.45
- QLGN 0.03
- Stochastic Oscillator
- XHG 13.92
- QLGN 69.82
About XHG XCHANGE TEC.INC SPON ADS EACH REP 600000 SHS(POST SPLIT)
XChange Tec Inc, through its subsidiaries operates in insurance agency and insurance technology business. The company specialized in distributing automobile insurance policies at the earlier stage of business and subsequently expanded insurance product portfolio to include other types of insurance including life, health, group accident and other property related insurances. A maximum of the insurance purchased through platform and agency services is of automobile insurance.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.